Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

The Effect of Nanoliposomal Curcumin (Cur-NLPs) Proliferation Rate with Cell Counting Kit 8 (CCK-8) and PI3K expression in cervical cancer HeLa cells

Universa Medicina · Vol. 45 No. 2 (2026) · hlm. 249–258

DOI
10.18051/UnivMed.2026.v45.249-258
ISSN
2407-2230, 1907-3062
Terbit
2026-07-21
Penerbit
Faculty of Medicine, Universitas Trisakti
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

INTRODUCTIONCervical cancer is a major health problem in developing countries. Cisplatin therapy has limitations related to toxicity and drug resistance associated with activation of the PI3K/AKT/mTOR pathway. Curcumin has anticancer activity, but its bioavailability is low; therefore, it has been developed in a nanoliposomal formulation. This study aimed to evaluate the effects of curcumin nanoliposomes (Cur-NLPs) on proliferation and PI3K expression of HeLa cells. METHODSAn experimental study was conducted using HeLa cells, divided into seven groups: negative control, cisplatin 5 µg/mL, and Cur-NLPs groups at 50, 100, 150, 200, and 250 µg/mL. Cell viability was measured using the cell counting kit-8 (CCK-8). Measurements were performed at 24 and 48 hours at a wavelength of 450 nm. Based on viability results, PI3K expression was analyzed at 48 hours using flow cytometry in five groups: negative control, cisplatin, and Cur-NLPs at 100, 150, and 200 µg/mL. Data were analyzed using one-way ANOVA followed by Games-Howell test. RESULTSCur-NLPs significantly reduced HeLa cell viability at 24 and 48 hours (p<0.001). The 200 µg/mL dose showed the most optimal antiproliferative effect, with viability of 38.3% at 24 hours and 18.0% at 48 hours. PI3K expression in the Cur-NLPs group (42.49–45.03%) was lower than that in the cisplatin group (66.78%), but the difference was not statistically significant (p=0.063). CONCLUSIONCur-NLPs inhibited HeLa cell viability in a dose- and time-dependent manner and showed a trend toward reduced PI3K expression. Further replication and analysis of downstream PI3K markers are needed to confirm these findings.

Kata kunci

Jaringan kolaborasi para penulis

9 penulis · 15 tautan kepenulisan bersama · 10 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • State University of Malang
  • RSUD Prof. Dr. Saiful Anwar Malang
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Nindi Kusuma DewiState University of Malang1
Herdhika Ayu Retno KusumasariState University of Malang1
Sri AndariniUniversity of Brawijaya1
Faiza Fardha AuliyaUniversity of Brawijaya1
Bambang RahardjoUniversity of Brawijaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://univmed.org/ejurnal/index.php/medicina/oai, pertama di-harvest 10 Nov 2026, terakhir terlihat 10 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">The Effect of Nanoliposomal Curcumin (Cur-NLPs) Proliferation Rate with Cell Counting Kit 8 (CCK-8) and PI3K expression in cervical cancer HeLa cells</dc:title>
	<dc:creator xml:lang="en"> Subandi,  Subandi</dc:creator>
	<dc:creator xml:lang="en">Suciati, Ferry</dc:creator>
	<dc:creator xml:lang="en">Arifiandi, Maya Devi </dc:creator>
	<dc:creator xml:lang="en">Indrawan, I Wayan Agung </dc:creator>
	<dc:subject xml:lang="en">Nanoliposomal curcumin</dc:subject>
	<dc:subject xml:lang="en">HeLa cells</dc:subject>
	<dc:subject xml:lang="en">cervical cancer</dc:subject>
	<dc:subject xml:lang="en">cell proliferation</dc:subject>
	<dc:subject xml:lang="en">PI3K</dc:subject>
	<dc:subject xml:lang="en">flow cytometry</dc:subject>
	<dc:description xml:lang="en">INTRODUCTIONCervical cancer is a major health problem in developing countries. Cisplatin therapy has limitations related to toxicity and drug resistance associated with activation of the PI3K/AKT/mTOR pathway. Curcumin has anticancer activity, but its bioavailability is low; therefore, it has been developed in a nanoliposomal formulation. This study aimed to evaluate the effects of curcumin nanoliposomes (Cur-NLPs) on proliferation and PI3K expression of HeLa cells.
METHODSAn experimental study was conducted using HeLa cells, divided into seven groups: negative control, cisplatin 5 µg/mL, and Cur-NLPs groups at 50, 100, 150, 200, and 250 µg/mL. Cell viability was measured using the cell counting kit-8 (CCK-8). Measurements were performed at 24 and 48 hours at a wavelength of 450 nm. Based on viability results, PI3K expression was analyzed at 48 hours using flow cytometry in five groups: negative control, cisplatin, and Cur-NLPs at 100, 150, and 200 µg/mL. Data were analyzed using one-way ANOVA followed by Games-Howell test.
RESULTSCur-NLPs significantly reduced HeLa cell viability at 24 and 48 hours (p&amp;lt;0.001). The 200 µg/mL dose showed the most optimal antiproliferative effect, with viability of 38.3% at 24 hours and 18.0% at 48 hours. PI3K expression in the Cur-NLPs group (42.49–45.03%) was lower than that in the cisplatin group (66.78%), but the difference was not statistically significant (p=0.063).
CONCLUSIONCur-NLPs inhibited HeLa cell viability in a dose- and time-dependent manner and showed a trend toward reduced PI3K expression. Further replication and analysis of downstream PI3K markers are needed to confirm these findings.</dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Universitas Trisakti</dc:publisher>
	<dc:date>2026-07-21</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://univmed.org/ejurnal/index.php/medicina/article/view/1954</dc:identifier>
	<dc:identifier>10.18051/UnivMed.2026.v45.249-258</dc:identifier>
	<dc:source xml:lang="en">Universa Medicina; Vol. 45 No. 2 (2026); 249-258</dc:source>
	<dc:source>2407-2230</dc:source>
	<dc:source>1907-3062</dc:source>
	<dc:source>10.18051/UnivMed.2026.v45.i2</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/1954/882</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2026  Subandi  Subandi, Ferry Suciati, Maya Devi  Arifiandi, I Wayan Agung  Indrawan</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>